Evidence map›Paper›PMID 42100666›Full record

ArticleAdvanced functional materials2026

Resonance Energy Transfer-Driven Photothermal Nanoagent Enables Melanoma Ablation Under Low-Power Near-Infrared Irradiation.

Prem Singh, Constanze Raitmayr, Syed Zaki Husain Rizvi, Ammar Salem, Vladislav Grigoriev, Tetiana Korzun, Karthickraja Duraisamy, Akshay Vyawahare, Kongbrailatpam Shitaljit Sharma, Ana Paula Mesquita Souza and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced functional materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Prem SinghDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 SW Moody Avenue, Portland, Oregon, 97201, USA.
Constanze RaitmayrDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 SW Moody Avenue, Portland, Oregon, 97201, USA.
Syed Zaki Husain RizviDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 SW Moody Avenue, Portland, Oregon, 97201, USA.
Ammar SalemDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 SW Moody Avenue, Portland, Oregon, 97201, USA.
Vladislav GrigorievDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 SW Moody Avenue, Portland, Oregon, 97201, USA.
Tetiana KorzunDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 SW Moody Avenue, Portland, Oregon, 97201, USA.
Karthickraja DuraisamyDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 SW Moody Avenue, Portland, Oregon, 97201, USA.
Akshay VyawahareDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 SW Moody Avenue, Portland, Oregon, 97201, USA.
Kongbrailatpam Shitaljit SharmaDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 SW Moody Avenue, Portland, Oregon, 97201, USA.
Ana Paula Mesquita SouzaDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 SW Moody Avenue, Portland, Oregon, 97201, USA.
Yitayal Admassu WorkieDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 SW Moody Avenue, Portland, Oregon, 97201, USA; Department of Industrial Chemistry, Addis Ababa Science and Technology University, Addis Ababa 1647, Ethiopia; Nanotechnology Center of Excellence, Addis Ababa Science and Technology University, Addis Ababa 1647, Ethiopia.
Yoon Tae GooDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 SW Moody Avenue, Portland, Oregon, 97201, USA.
Manali P PhawdeDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 SW Moody Avenue, Portland, Oregon, 97201, USA.
Chrissa KioussiDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 SW Moody Avenue, Portland, Oregon, 97201, USA; Department of Pharmaceutical Sciences, Oregon State University, 1601 SW Jefferson Avenue, Corvallis, Oregon, 97331, USA.
Adam Wg AlaniDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 SW Moody Avenue, Portland, Oregon, 97201, USA.
Oleh TaratulaDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 SW Moody Avenue, Portland, Oregon, 97201, USA.
Olena R TaratulaDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 SW Moody Avenue, Portland, Oregon, 97201, USA.

Funding

Novel Nanomedicine-Based Therapeutic Approach For Treatment of Cancer CachexiaR37CA234006 · NCI · OREGON STATE UNIVERSITY · PI TARATULA, OLEH · 2019 to 2025
$3.2M
Intravascular Delivery of Nanoclusters for Treatment of Deep-Seated Cancers with Magnetic HyperthermiaR01CA237569 · NCI · OREGON STATE UNIVERSITY · PI TARATULA, OLEH · 2020 to 2024
$2.7M
Nanoparticle-mediated placental imaging and magnetic hyperthermia for management of ectopic pregnancyR01HD112007 · NICHD · OREGON STATE UNIVERSITY · PI Olena Taratula · 2023 to 2026
$2.4M
Development of magnetic hyperthermia for the systemic treatment of endometriosisR01HD101450 · NICHD · OREGON STATE UNIVERSITY · PI SLAYDEN, OV D, TARATULA, OLEH · 2021 to 2024
$2.4M
NCI NIH HHS R01 CA237569NCI NIH HHS R37 CA234006NICHD NIH HHS R01 HD101450NICHD NIH HHS R01 HD112007
6 · The paper itself

Abstract

Photothermal therapy (PTT) utilizes near-infrared (NIR) light to activate photothermal agents, enabling localized tumor ablation. However, conventional agents require high laser power densities to reach therapeutic temperatures, exceeding the skin safety limit of 0.33 W/cm

Indexed as

Gold nanorodsNear-infrared-IPhotothermal therapyResonance energy transfer (RET)silicon naphthalocyanine (SiNc)Transgenic melanoma

Identifiers

PMID42100666
PMCPMC13148416

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.